New pathogenic treatments for myasthenia gravis DOI

Т. М. Алексеева,

P. Sh. Isabekova, E.I. Kondratova

et al.

S S Korsakov Journal of Neurology and Psychiatry, Journal Year: 2025, Volume and Issue: 125(1), P. 31 - 31

Published: Feb. 11, 2025

Myasthenia gravis (MG) is an autoimmune disease caused by the production of specific autoantibodies to various components neuromuscular synapse, leading muscle weakness and disabling fatigue. Treatment MG aims stop symptoms inhibit triggers process. For a long time, treatment included anticholinesterase agents nonspecific immunosuppressive immunomodulatory therapies used alone or in combinations: glucocorticosteroids, cytostatics, plasmapheresis, intravenous immunoglobulin. Despite fact that above drugs are widely MG, they can cause unacceptable side effects with long-term use also not consistent induction remission. The search for new effective safe especially refractory types do respond standard therapy, urgent task. Due advances biotechnology emergence drugs, monoclonal antibodies fusion proteins, targeted immunotherapy has been developed pathogenetic targets. presented review describes already approved In Russia other countries, as well those at different stages development. Most have some advantages over traditional therapy: rapid onset action, remission, minimal effects. Currently, eculizumab ravulizumab Russia.

Language: Английский

New pathogenic treatments for myasthenia gravis DOI

Т. М. Алексеева,

P. Sh. Isabekova, E.I. Kondratova

et al.

S S Korsakov Journal of Neurology and Psychiatry, Journal Year: 2025, Volume and Issue: 125(1), P. 31 - 31

Published: Feb. 11, 2025

Myasthenia gravis (MG) is an autoimmune disease caused by the production of specific autoantibodies to various components neuromuscular synapse, leading muscle weakness and disabling fatigue. Treatment MG aims stop symptoms inhibit triggers process. For a long time, treatment included anticholinesterase agents nonspecific immunosuppressive immunomodulatory therapies used alone or in combinations: glucocorticosteroids, cytostatics, plasmapheresis, intravenous immunoglobulin. Despite fact that above drugs are widely MG, they can cause unacceptable side effects with long-term use also not consistent induction remission. The search for new effective safe especially refractory types do respond standard therapy, urgent task. Due advances biotechnology emergence drugs, monoclonal antibodies fusion proteins, targeted immunotherapy has been developed pathogenetic targets. presented review describes already approved In Russia other countries, as well those at different stages development. Most have some advantages over traditional therapy: rapid onset action, remission, minimal effects. Currently, eculizumab ravulizumab Russia.

Language: Английский

Citations

0